Biohaven Pharmaceutical Holding logo

Biohaven Pharmaceutical HoldingNYSE: BHVN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 September 2022

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.73 B
-13%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector
-77%vs. 3y high
94%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 22:09:51 GMT
$50.02-$2.22(-4.25%)

Dividend

No data over the past 3 years
$9.09 M$9.09 M

Analysts recommendations

Institutional Ownership

BHVN Latest News

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
prnewswire.com02 October 2024 Sentiment: POSITIVE

NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
prnewswire.com01 October 2024 Sentiment: NEUTRAL

NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.

Biohaven Announces Proposed Public Offering of Common Shares
prnewswire.com30 September 2024 Sentiment: NEUTRAL

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
zacks.com24 September 2024 Sentiment: POSITIVE

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
marketbeat.com24 September 2024 Sentiment: POSITIVE

Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).

Overlooked Stock: BHVN
youtube.com23 September 2024 Sentiment: POSITIVE

Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.

Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
investopedia.com23 September 2024 Sentiment: POSITIVE

Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.

Biohaven's stock surges as treatment slows progress of neurological disorder
marketwatch.com23 September 2024 Sentiment: POSITIVE

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.

Biohaven's genetic disease drug meets main trial goal
reuters.com23 September 2024 Sentiment: POSITIVE

Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
prnewswire.com20 September 2024 Sentiment: POSITIVE

Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.

  • 1(current)

What type of business is Biohaven Pharmaceutical Holding?

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

What sector is Biohaven Pharmaceutical Holding in?

Biohaven Pharmaceutical Holding is in the Healthcare sector

What industry is Biohaven Pharmaceutical Holding in?

Biohaven Pharmaceutical Holding is in the Biotechnology industry

What country is Biohaven Pharmaceutical Holding from?

Biohaven Pharmaceutical Holding is headquartered in United States

When did Biohaven Pharmaceutical Holding go public?

Biohaven Pharmaceutical Holding initial public offering (IPO) was on 23 September 2022

What is Biohaven Pharmaceutical Holding website?

https://www.biohaven.com

Is Biohaven Pharmaceutical Holding in the S&P 500?

No, Biohaven Pharmaceutical Holding is not included in the S&P 500 index

Is Biohaven Pharmaceutical Holding in the NASDAQ 100?

No, Biohaven Pharmaceutical Holding is not included in the NASDAQ 100 index

Is Biohaven Pharmaceutical Holding in the Dow Jones?

No, Biohaven Pharmaceutical Holding is not included in the Dow Jones index

When was Biohaven Pharmaceutical Holding the previous earnings report?

No data

When does Biohaven Pharmaceutical Holding earnings report?

The next expected earnings date for Biohaven Pharmaceutical Holding is 14 November 2024